About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsTablets Medicines

Adco - Diclofenac Tablets 25MG 50MG 75MG Antipyretic - Analgesic Medicines

Have rich experience for this fireld, Competitive price, Fast delivery and Excellent service.

—— Javed Abdullah

A professional company,have a hard working team,very friendly

—— Puvi Manohar

I'm Online Chat Now

Adco - Diclofenac Tablets 25MG 50MG 75MG Antipyretic - Analgesic Medicines

China Adco - Diclofenac Tablets 25MG 50MG 75MG Antipyretic - Analgesic Medicines supplier

Large Image :  Adco - Diclofenac Tablets 25MG 50MG 75MG Antipyretic - Analgesic Medicines

Product Details:

Place of Origin: China
Brand Name: HL
Certification: GMP
Model Number: 250MG/50MG/75MG

Payment & Shipping Terms:

Minimum Order Quantity: 1,000,000 tablets
Price: Negotiation
Packaging Details: 10*10TABLETS/BOX*200/CATON
Delivery Time: Negotiation
Payment Terms: T/T, L/C, D/A, Western Union
Supply Ability: 30,000,000 tablets per month
Contact Now
Detailed Product Description
Product Name: ADCO-DICLOFENAC Tablets Composition: Each Enteric-coated Tablet Contains 25 Mg/50 Mg Diclofenac Sodium.
Standard: BP Package: 10*10TABLETS/BOX*200/CATON
Indications: Inflammatory And Degenerative Forms Of Rheumatism, Rheumatoid Arthritis, Ankylosing Spondylitis, Osteo-arthrosis, Painful Post-operative And Post-traumatic Inflammation And Swelling And Dysmenorrhoea. Storage Instructions: Store Below 25°C. Protect From Light And Moisture.
Expiration Date: 3 Years Identification: 25 Mg Tablet: Yellow, Round Enteric-coated. 50 Mg Tablet: Tan Coloured, Round, Enteric-coated.
High Light:

medicine tablets


medication pills

ADCO-DICLOFENAC  Tablets 25MG 50MG 75MG  Antipyretic-analgesic 10*10's / Box





Each enteric-coated tablet contains 25 mg or 50 mg diclofenac sodium.
Sugar free.



Diclofenac sodium is a non-steroidal compound, a phenylacetic acid derivative, with analgesic, antipyretic and anti-inflammatory effects. Diclofenac sodium inhibits the biosynthesis and release of prostaglandins, which are known to be implicated in the pathogenesis of inflammation, pain and fever. ADCO-DICLOFENAC Tablets are enteric-coated so that absorption occurs in the gastrointestinal tract to give peak plasma concentrations approximately 2 hours after ingestion. There is at least 99% binding to plasma-proteins and excretion of metabolites is mainly in the urine. 



Inflammatory and degenerative forms of rheumatism, rheumatoid arthritis, ankylosing spondylitis, osteo-arthrosis, painful post-operative and post-traumatic inflammation and swelling and dysmenorrhoea.



Diclofenac sodium is contra-indicated in patients with known hypersensitivity to diclofenac and in patients who respond to aspirin and aspirin-type drugs with sensitivity reactions like asthma, acute rhinitis and urticaria. Diclofenac sodium is absolutely contra-indicated in patients with peptic ulceration or a history of such ulceration, and should be used with caution in patients with renal or hepatic insufficiency.


The safe use of ADCO-DICLOFENAC in pregnancy has not been demonstrated.
Regular use of NSAID’s during the third trimester of pregnancy may result in premature closure of the foetal ductus arteriosus in utero and possibly in persistent pulmonary hypertension of the newborn. The onset of labour may be delayed and its duration increased.



Usual Adult Dose:
25 to 50 mg taken three times daily. The tablet must be taken whole during or after meals. Initially this dose may be increased to 150 mg daily and may be reduced to 75 to 100 mg daily in milder cases or for long-term and maintenance therapy. Diclofenac sodium is not recommended for use in children as safety and efficacy have not been established



In view of the product’s inherent potential to cause fluid retention, heart failure may be precipitated in some compromised patients.
Gastric or intestinal ulceration with associated bleeding has been reported - ADCO-DICLOFENAC therapy should be discontinued immediately in such cases. Skin rashes and gastro-intestinal disturbances may occur. Headache, dizziness, oedema, nervousness, pruritus, tinnitus, insomnia, blurred vision and other ocular reactions, peripheral oedema, malaise, jaundice, elevated transaminase levels, drowsiness and hypersensitivity reactions (eg. bronchospasm) have occurred. Blood counts and monitoring of hepatic and renal function are advised during prolonged therapy with ADCO-DICLOFENAC as blood dyscrasias have been reported. ADCO-DICLOFENAC should be given with care to patients with bleeding disorders, cardiovascular disease, and in those who are receiving coumarin anticoagulants. Patients who are sensitive to aspirin generally should not be given ADCO-DICLOFENAC.


Store below 25°C. Protect from light and moisture. Keep out of reach of children.

Contact Details

Contact Person: Mr. Zhang

Tel: 86--13738134030

Send your inquiry directly to us (0 / 3000)